文献情報

論文

臨床
NEW
Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET.
Hijioka S., et al. : Cancer Chemother Pharmacol. 2018 Oct 11. PubMed
NEW
Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.
Shibuya H., et al. : Cancer Chemother Pharmacol. 2018 Oct ; 82(4) : 661-668 PubMed
1)
Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.
Moertel CG., et al. : N Engl J Med. 1992 ; 326(8) : 519-523. PubMed
2)
Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.
Dahan L., et al. : Endocr Relat Cancer. 2009 ; 16(4) : 1351-1361. PubMed
3)
Fate of streptozotocin (NSC-85998)in patients with advanced cancer.
Adolphe AB., et al. : Cancer Chemother Rep. 1975 ; 59(3) : 547-556. PubMed
4)
Nephrotoxicity of streptozotocin (NSC-85998).
Sadoff L. : Cancer Chemother Rep. 1970 ; 54(6) : 457-459. PubMed
5)
Phase II study of strepozotocin (NSC-85998) in the treatment of advanced gastrointestinal cancer.
Moertel CG., et al. : Cancer Chemother Rep. 1971 ; 55(3) : 303-307. PubMed
6)
Streptozotocin in the treatment of cancer: phase II study.
Strolinsky DC., et al. : Cancer. 1972 ; 30(1) : 61-67. PubMed
7)
Pancreatic islet cell carcinoma. I. Clinical features of 52 patients.
Broder LE., et al. : Ann Intern Med. 1973 ; 79(1) : 101-107. PubMed
8)
Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients.
Broder LE., et al. : Ann Intern Med. 1973 ; 79(1) : 108-118. PubMed
9)
Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.
Moertel CG., et al. : Cancer Clin Trials. 1979 ; 2(4) : 327-334. PubMed
10)
Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.
Moertel CG., et al. : N Engl J Med. 1980 ; 303(21) : 1189-1194. PubMed
11)
Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor.
Engstrom PF., et al. : J Clin Oncol. 1984 ; 2(11) : 1255-1259. PubMed
12)
A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study.
Bukowski RM., et al. : Cancer. 1987 ; 60(12) : 2891-2895. PubMed
13)
Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin--alone or in combination with 5-FU.
Oberg K., et al. Acta Oncol. 1987 ; 26(6) : 429-432. PubMed
14)
Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon.
Oberg K., et al. Eur J Cancer Clin Oncol. 1989 Oct ; 25(10) : 1475-1479. PubMed
15)
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?
Delaunoit T., et al. : Eur J Cancer. 2004 ; 40(4) : 515-520. PubMed
16)
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.
Kouvaraki MA., et al. : J Clin Oncol. 2004 ; 22(23) : 4762-4771. PubMed
17)
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
Sun W., et al. : J Clin Oncol. 2005 ; 23(22) : 4897-4904. PubMed
18)
Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.
Dahan L., et al. Endocr Relat Cancer. 2009 Dec ; 16(4) : 1351-1361. PubMed
19)
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.
Turner NC., et al. : Br J Cancer. 2010 ; 102(7) : 1106-1112. PubMed
20)
Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan.
Aoki T., et al. : J Gastroenterol. 2015 ; 50(7) : 769-775. PubMed
21)
Optimising Therapeutic Options for Patients with Advanced Pancreatic Neuroendocrine Tumours
Yao J., Phan AT. : Eur Oncol Haematology. 2012 ; 8(4):217-223. touchONCOLOGY.com
22)
Streptozocin-based chemotherapy is not history in neuroendocrine tumours.
Weatherstone K., Meyer T. : Target Oncol. 2012 ; 7(3) : 161-168. PubMed
23)
A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series.
Naidoo J., et al. : Ir J Med Sci. 2012 ; 181(2) : 211-214. PubMed
24)
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Meyer T., et al. : Eur J Cancer. 2014 ; 50(5) : 902-911. PubMed
25)
Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors.
Prakash L.,et al. : J Gastrointest Surg. 2017 ; 21(1) : 155-163. PubMed
26)
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
Ducreux M., et al. Eur J Cancer. 2014 Dec ; 50(18) : 3098-3106 PubMed
27)
Carcinoid and neuroendocrine tumors: building on success.
Kunz PL. : J Clin Oncol. 2015 ; 33 (16) : 1855-1863. PubMed
28)
Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification.
Krug S., et al. : PLoS One. 2015 ; 10(12) : e0143822. PubMed
29)
Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
Dilz LM., et al. : Eur J Cancer. 2015 ; 51(10) : 1253-1262. PubMed
30)
Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity.
Antonodimitrakis P., et al. : Neuroendocrinology. 2016 ; 103(3-4) : 345-353. PubMed
31)
Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy.
Krug S., et al. Pancreatology. 2017 Jan - Feb ; 17(1) : 139-145 PubMed
32)
Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience.
Dhir M., et al. Ann Surg Oncol. 2017 Feb ; 24(2) : 450-459. PubMed
33)
The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
Krug S., et al. Digestion. 2017 Jul 21 ; 96(2) : 67-75. PubMed
<相互作用・過量投与 等>
34)
Combination chemotherapy with adriamycin and streptozotocin. II. Clincopharmacologic correlation of augmented adriamycin toxicity caused by streptozotocin.
Chang P., et al. : Clin Pharmacol Ther. 1976 ; 20(5) : 611-616. PubMed
35)
Influence of diphenylhydantoin on the effect of streptozotocin.
Koranyi L., Gero L. : Br Med J. 1979 Jan 13 ; 1(6156) : 127. PubMed
36)
Clinical antitumor activity and toxicity of streptozotocin (NSC-85998).
Schein PS., et al. : Cancer. 1974 ; 34(4) : 993-1000. PubMed
非臨床
<薬物体内動態>
1)
Distribution of labelled streptozotocin in mice: uptake and retention in pancreatic islets.
Tjälve H., et al. : J Endocrinol. 1976 ; 69(3) : 455-456. PubMed
2)
STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells.
Schnedl WJ., et al. : Diabetes. 1994 ; 43(11) : 1326-1333. PubMed
3)
Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes.
Shimojo N., et al. : Biochem Pharmacol. 1993 ; 46(4) : 621-627. PubMed
4)
Differential regulation of hepatic cytochrome P450 monooxygenases in streptozotocin-induced diabetic rats.
Sindhu RK., et al. : Free Radic Res. 2006 ; 40(9) : 921-928. PubMed
5)
Comparison of alloxan and streptozotocin induced diabetes in rats: differential effects on microsomal drug metabolism.
Vega P., et al. : Gen Pharmacol. 1993 ; 24(2) : 489-495. PubMed
<薬効薬理>
6)
Cytotoxicity of streptozotocin on neuroendocrine cells of the pancreas and the gut.
Brenna O., et al. : Dig Dis Sci. 2003 ; 48(5) : 906-910. PubMed
7)
Genotoxicity of streptozotocin.
Bolzán AD, Bianch MS. : Mutat Res. 2002 ; 512(2-3) : 121-134. PubMed
8)
Alkylation of DNA in rat tissues following administration of streptozotocin.
Benett RA., et al. : Cancer Res. 1981 ; 41(7) : 2786-2790. PubMed
9)
The action of streptozotocin on mammalian cells.
Bhuyan BK. : Cancer Res. 1970 ; 30(7) : 2017-2023. PubMed
10)
Streptozotocin induces G2 arrest in skeletal muscle myoblasts and impairs muscle growth in vivo.
Johnston AP., et al. : Am J Physiol Cell Physiol. 2007 ; 292(3) : C1033-C1040. PubMed
11)
Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation of O6-alkylguanine-DNA alkyltransferase.
Gerson SL., et al. : Cancer Res. 1988 ; 48(6) : 1521-1527. PubMed
12)
Effects of cytotoxic drugs and inhibitors of insulin secretion on a serially transplantable rat insulinoma and cultured rat insulinoma cells.
Flatt PR., et al. : Gen Pharmacol. 1987 ; 18(3) : 293-297. PubMed
13)
Antileukemic activity of streptozotocin (NSC-85998) and its analogs.
Bhuyan BK., et al. : Cancer Chemother Rep. 1972 ; 56(6) : 709-720. PubMed
<一般薬理>
14)
Effects of changes in peripheral and cerebral glucose metabolism on locomotor activity, learning and memory in adult male rats.
Mayer G., et al. : Brain Res. 1990 ; 532(1-2) : 95-100. PubMed
15)
Changes in collagen and elastin of the rat aorta induced by experimental diabetes and food restriction.
Andreassen TT., et al. : Acta Endocrinol(Copenh). 1987 ; 115(3) : 338-344. PubMed
16)
A functional and ultrastructural analysis of experimental diabetic rat myocardium. Manifestation of a cardiomyopathy.
Jackson CV., et al. : Diabetes. 1985 ; 34(9) : 876-883. PubMed
17)
Influence of short-term experimental diabetes on blood pressure and heart rate in response to norepinephrine and angiotensin II in the conscious rat.
Jackson CV., et al. : J Cardiovasc Pharmacol. 1983 ; 5(2) : 260-265. PubMed
18)
Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury.
Eizirik DL., et al. : Proc Natl Acad Sci. 1994 ; 91(20) : 9253-9256. PubMed
19)
Diabetogenic action of streptozotocin: relationship of dose to metabolic response.
Junod A., et al. : J Clin Invest. 1969 ; 48(11) : 2129-2139. PubMed
20)
The effect of low versus high dose of streptozotocin in cynomolgus monkeys (Macaca fascilularis).
Koulmanda M., et al. : Am J Transplant. 2003 ; 3(3) : 267-272. PubMed
21)
Streptozotocin- and alloxan-diabetes in mice.
Rerup C., et al. : Eur J Pharmacol. 1969 ; 7(1) : 89-96. PubMed
22)
Streptozotocin-diabetes in the Chinese hamster. Blood glucose and structural changes during the first 24 hours.
Wilander E., et al. : Hor Metab Res. 1972 ; 4(6) : 426-433. PubMed
23)
Delayed stomach to caecum transit time in the diabetic rat. Possible role of hyperglucagonaemia.
Chesta J., et al. : Gut. 1990 ; 31(6) : 660-662. PubMed
24)
Compliance changes of the gastrointestinal tract in streptozotocin-induced diabetic rats.
Karakida T., et al. : Jpn J Physiol 1989 ; 39(4) : 559-570. PubMed
25)
The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.
Longhurst PA., et al. : Gen Pharmacol. 1991 ; 22(2) : 305-311. PubMed
26)
Impaired erythrocyte deformability precedes vascular changes in experimental diabetes mellitus.
Diamantopoulos EJ., et al. : Horm Metab Res. 2004 ; 36(3) : 142-147. PubMed

ガイドライン

1)
NCCN : NCCN Clinical Practice Guidelines in Oncology, Neuroendocrine Tumors Ver.2(2014).
2)
NCCN : NCCN Clinical Practice Guidelines in Oncology, Neuroendocrine Tumors Ver.2(2016).
3)
NCCN : NCCN Clinical Practice Guidelines in Oncology, Neuroendocrine Tumors Ver.3(2017)
4)
(ENETS Consensus Guidelines) Eriksson B., et al. : Neuroendocrinology.
2009 ; 90(2) : 214-219.PubMed
5)
(ENETS Consensus Guidelines) Pavel M., et al. : Neuroendocrinology. 2012 ; 95(2) : 157-176.PubMed
6)
(ENETS Consensus Guidelines) Pavel M., et al. Neuroendocrinology. 2016 ; 103(2) : 172-185.PubMed
7)
(NANETS Treatment Guidelines) Kulke MH., et al. : Pancreas. 2010 ; 39(6) : 735-752.PubMed
8)
(NANETS Treatment Guidelines) Boudreaux JP., et al. : Pancreas. 2010 ; 39(6) : 753-766.PubMed
9)
固形がんの治療効果判定のための新ガイドライン(RECISTガイドライン)−改訂版version 1.1− 日本語訳 JCOG版 ver.1.0(2010年6月)
10)
膵・消化管神経内分泌腫瘍(NET)診療ガイドライン第1版(2015年4月、膵・消化管神経内分泌腫瘍(NET)診療ガイドライン作成委員会 編)

国際的教科書

1)
Yao JC., et al. : Chapter Ⅲ. Pancreatic neuroendocrine tumors. In : DeVita VT. et al. ed.,Cancer Principle and practice of oncology 9th Ed., (Philadelphia, Lippincott Williams & Wilkins, a Wolters Kluwer, 2011), p.1489-1502.
2)
NCI : National Cancer Institute Physician Data Query (2015)NCI-PDQ